AB-Gen: Antibody Library Design with Generative Pre-Trained Transformer and Deep Reinforcement Learning
Open accessPublished version of a preprint
Abstract
Antibody leads must fulfill multiple desirable properties to be clinical candidates. Primarily due to the low throughput in the experimental procedure, the need for such multi-property optimization causes the bottleneck in preclinical antibody discovery and development, because addressing one issue usually causes another. We developed a reinforcement learning (RL) method, named AB-Gen, for antibody library design using a generative pre-trained transformer (GPT) as the policy network of the RL agent. We showed that this model can learn the antibody space of heavy chain complementarity determining region 3 (CDRH3) and generate sequences with similar property distributions. Besides, when using human epidermal growth factor receptor-2 (HER2) as the target, the agent model of AB-Gen was able to generate novel CDRH3 sequences that fulfill multi-property constraints. Totally, 509 generated sequences were able to pass all property filters, and three highly conserved residues were identified. The importance of these residues was further demonstrated by molecular dynamics simulations, consolidating that the agent model was capable of grasping important information in this complex optimization task. Overall, the AB-Gen method is able to design novel antibody sequences with an improved success rate than the traditional propose-then-filter approach. It has the potential to be used in practical antibody design, thus empowering the antibody discovery and development process. The source code of AB-Gen is freely available at Zenodo (https://doi.org/10.5281/zenodo.7657016) and BioCode (https://ngdc.cncb.ac.cn/biocode/tools/BT007341).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764 · see citing works
The coming of age of de novo protein design
Huang, P.-S., Boyken, S. E., & Baker, D. (2016) · Nature · doi:10.1038/nature19946 · Cited by 1,478 · see citing works
De novo protein design by deep network hallucination
Anishchenko, I., Chidyausiku, T. M., Ovchinnikov, S., Pellock, S. J., & Baker, D. (2020) · doi:10.1101/2020.07.22.211482 · Cited by 629 · see citing works
The CamSol method of rational design of protein mutants with enhanced solubility
Sormanni, P., Aprile, F. A., & Vendruscolo, M. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.09.026 · Cited by 494 · see citing works
Mason, D. M., Friedensohn, S., Weber, C. R., Jordi, C., Wagner, B., Meng, S. M., Ehling, R. A., Bonati, L., Dahinden, J., Gainza, P., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00699-9 · Cited by 308 · see citing works
Computational approaches to therapeutic antibody design: established methods and emerging trends
Norman, R. A., Ambrosetti, F., Bonvin, A. M. J. J., Colwell, L. J., Kelm, S., Kumar, S., & Krawczyk, K. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz095 · Cited by 219 · cited 1× · see citing works
“For targets with no such data-sets, antibody–antigen docking platforms provide alternative solutions [31,32].”
BackgroundIn silico proof of principle of machine learning-based antibody design at unconstrained scale
Akbar, R., Robert, P. A., Weber, C. R., Widrich, M., Frank, R., Pavlović, M., Scheffer, L., Chernigovskaya, M., Snapkov, I., Slabodkin, A., et al. (2022) · mAbs · doi:10.1080/19420862.2022.2031482 · Cited by 94 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Explainable artificial intelligence for multi-modal cancer analysis: from genomics to immunology
Zhang, M., & Yin, L. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105040 · Cited by 5 · see citing works
- Authors
- Xu, X., Xu, T., Zhou, J., Liao, X., Zhang, R., Wang, Y., Zhang, L., & Gao, X.
- Affiliations
- King Abdullah University of Science and Technology (SA)
- Chinese Academy of Sciences (CN)
- Syneron Technology , Guangzhou, 510000 , China
- Corresponding author
- Gao, Xin
- Venue
- Genomics, Proteomics & Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-06-24
- Volume
- 21
- Issue
- 5
- Pages
- 1043-1053
- ISSN
- 1672-0229 (ISSN-L)
- 2210-3244
- PMC
- PMC10928431
- OpenAlex
- W4381848602
- Cited by
- 32
- References
- 7
- Citations by year
- 2026: 14 · 2025: 10 · 2024: 6 · 2023: 2
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Genomics Proteomics & Bioinformatics (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- King Abdullah University of Science and Technology Repository (King Abdullah University of Science and Technology) (submittedVersion, cc-by-nc-nd)
- Funders
- King Abdullah University of Science and Technology (FCC/1/1976-44-01, FCC/1/1976-45-01, REI/1/5234-01-01, URF/1/4352-01-01)
- National Natural Science Foundation of China (22273107)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Keywords
- generative pre-trained transformer, deep reinforcement learning, multi-property optimization, HER2, antibody discovery, molecular dynamics, conserved residues
- MeSH terms
- Antibodies, Humans, Software, Gene Library, Molecular Dynamics Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review